Taro Pharma (TARO) Reports Q3 EPS of $3.33

Taro Pharma (NYSE: TARO) reported Q3 EPS of $3.33, versus $2.59 reported last year. Revenue for the quarter came in at $237.7 million, versus $213.6 million reported last year.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat